Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ISENTRESS tablets, an integrase inhibitor from Merck and Co., Inc., Whitehouse Station, N.J., U.S.A., was as effective as efavirenz at maintaining viral load suppression to undetectable levels and at improving CD4 counts in previously untreated patients through 144 weeks in a Phase II study still underway. Both medicines were administered in combination with two other anti–HIV medicines, tenofovir and lamivudine. These results were presented today at the 5th International AIDS Society's Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa.

Related Articles

Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09    Relevance Score: 95%

HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09    Relevance Score: 95%

Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09    Relevance Score: 94%

Sperm May Play Leading Role In Spreading HIV
ScienceDaily, 10/27/09    Relevance Score: 94%

Female sex work and HIV risks in Croatia
AIDS Care, 10/29/09    Relevance Score: 93%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address